A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combination of Ipilimumab Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Hodgkin Lymphoma
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1. Confirmed diagnosis of Relapsed/Refractory Hodgkin Lymphoma.

    2. Patients must have relapsed after first line chemotherapy.

    3. All prior therapy must have been completed at least 21 days prior to enrollment.

    4. No existing hypersensitivity to brentuximab vedotin or ipilimumab.

You may not be eligible for this study if the following are true:

  • 1.  Patients with current or prior history of CNS involvement

    2.  History of Steven's Johnson syndrome, TENs syndrome, or motor neuropathy

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.